Cyclerion Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 1
- Market Cap
- $6.9M
- Website
- http://www.cyclerion.com
- Introduction
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Calluna Pharma Appoints Mark Gaffney as CEO, Advances CAL101 Program
• Calluna Pharma has appointed Mark Gaffney as Chief Executive Officer to lead the company's strategic initiatives and advance its pipeline.
• Gaffney's appointment coincides with Calluna's lead candidate, CAL101, nearing completion of its Phase 1 program for inflammatory and fibrotic diseases.
• Mark Altmeyer has also been appointed as the Independent Chair of the Board, bringing extensive leadership experience in the pharmaceutical and biotech sectors.
• Calluna Pharma is focused on developing first-in-class antibodies targeting the root causes of inflammation and fibrosis.
© Copyright 2025. All Rights Reserved by MedPath